Aspira Women’s Health 

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aspira Women's Health (AWH) sees robust growth and innovation in Q1 2024

Aspira Women's Health (AWH) reported strong performance in Q1 2024, driven by significant growth in test volumes and improvements in financial metrics. The company's focus on innovation and collaboration underscores its commitment to advancing women's health diagnostics. While challenges in funding persist, AWH's strategic initiatives and market opportunities position it for continued growth and success in the future.

Aspira Women's Health achieves record test volumes amidst cost challenges

AWH reported strong performance in test volumes and revenue growth in Q2 2024.
While facing challenges with margins and costs, the company is actively addressing them.
Opportunities lie in product development, market expansion, and cost control measures.
Overall, AWH is strategically positioned for growth and innovation in the women's health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Increased year-over-year product revenue by 26% to $2.0 million and year-over-year product volume by 29% to 5,524 units

Aspira Women's Health Reports Third Quarter 2022 Financial Results

AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will present and be available for 1x1 meetings at the MicroCap Rodeo Presents Windy City Roundup 2022 conference taking place in-person on October 12-13, 2022 in Chicago, IL. Details for the event are below:

Aspira Women's Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022

Aspira (AWH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Aspira (AWH) Looks Ripe for Bottom Fishing

Data demonstrates the accuracy of Aspira's multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125 in detecting early-stage cancer in women with a pelvic mass Data demonstrates the accuracy of Aspira's multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125 in detecting early-stage cancer in women with a pelvic mass

Aspira Women's Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women

The heavy selling pressure might have exhausted for Aspira (AWH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 38.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Aspira (AWH)

AUSTIN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, today announced it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities will be offered by Aspira.

Aspira Women's Health Inc. Announces Proposed Public Offering

KOL Event to take place on Wednesday, August 24th at 12:00pm ET KOL Event to take place on Wednesday, August 24th at 12:00pm ET

Aspira Women's Health Hosting Women's Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariant Index Assay

Aspira Women's Health, Inc. (NASDAQ:AWH ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Robert Beechey - Chief Financial Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Inc. Second Quarter 2022 Conference Call. My name is Vikram and I will be your coordinator for the call today.

Aspira Women's Health, Inc. (AWH) CEO Nicole Sandford on Q2 2022 Results - Earnings Call Transcript

Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units

Aspira Women's Health Reports Second Quarter 2022 Financial Results

AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, today announced that the company will report its financial results for the second quarter ended June 30, 2022 before the market open on Wednesday, August 10, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below:

Aspira Women's Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10

Seasoned Directors further strengthen Board with decades of industry and leadership experience Seasoned Directors further strengthen Board with decades of industry and leadership experience

Aspira Women's Health Announces Appointment of Two New Board Members

Paper published in the June online issue of JCO Clinical Cancer Informatics Paper published in the June online issue of JCO Clinical Cancer Informatics

Aspira Women's Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer

AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will participate in the “MicroCap Rodeo Spring Into Action Best Ideas” Conference virtually and the “William Blair 42nd Annual Growth Stock Conference” in Chicago. Details for both investor conferences are below:

Aspira Women's Health to Participate in the Upcoming Investor Conferences

Aspira Women's Health, Inc. (NASDAQ:AWH ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Nicole Sandford - President, Chief Executive Officer and Director Robert Beechey - Chief Financial Officer Michael Newton - Head, Commercial Conference Call Participants Brian Weinstein - William Blair & Company Ross Osborn - Cantor Fitzgerald & Co. Nicole Sandford Thank you, operator, and thank you to all of you for joining us today. I'll start with a business update before I hand the call over to Bob to review our Q1 financial performance.

Aspira Women's Health, Inc. (AWH) CEO Nicole Sandford on Q1 2022 Results - Earnings Call Transcript

Aspira (AWH) delivered earnings and revenue surprises of 0% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aspira (AWH) Reports Q1 Loss, Misses Revenue Estimates

Product Revenue Increased 30% to $1.8 million; OVA1plus Volume Grew 28% to 4,819 Units

Aspira Women's Health Reports First Quarter 2022 Financial Results

AUSTIN, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that the company will report its financial results for the first quarter ended March 31, 2022 before the market open on Wednesday, May 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below:

Aspira Women's Health to Announce First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 11

Aspira Women's Health Inc. (AWH) CEO Nicole Sanford on Q4 2021 Results - Earnings Call Transcript

Aspira (AWH) delivered earnings and revenue surprises of 11.11% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aspira (AWH) Reports Q4 Loss, Lags Revenue Estimates

Total Revenue Increased 46% to $6.8 million; OVA1 Volume Grew 28% to 17,359 Units

Aspira Women's Health Reports Fourth Quarter and Full Year 2021 Financial Results

AUSTIN, Texas, March 15, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that the company will report its financial results for the year ended December 31, 2021 before the market open on Wednesday, March 23, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below:

Aspira Women's Health to Announce Year End 2021 Financial Results and Host Conference Call on Wednesday, March 23

AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced the appointment of Celeste Fralick, Ph.D., to its Board of Directors, effective February 23, 2022.

Aspira Women's Health Announces Appointment of Celeste Fralick, Ph.D., to its Board of Directors

Expanded leadership team to drive strategic partnerships, accelerate new commercial launches, and grow overall enterprise value Expanded leadership team to drive strategic partnerships, accelerate new commercial launches, and grow overall enterprise value

Valerie Palmieri Elevated to Executive Chair of the Board; Nicole Sandford Appointed President and CEO

AUSTIN, Texas, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced the appointment of Mr. Michael Newton as Head of Sales and Marketing who brings to the company over twenty years of experience in the diagnostic healthcare area.

Aspira Women's Health, Inc. Expands Senior Leadership Team with Addition of Mr. Michael Newton as Head of Sales and Marketing

AUSTIN, Texas, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will participate in the 2nd Annual Winter Wonderland Best Ideas Conference taking place February 8th-11th, 2022. Details for the event are below:

News for Aspira Women’s Health Stock (AWH)